Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 454-461

  D'Souza, Ajit Joseph M ^a   Mar, Kevin D ^a   Huang, Joanne ^a   Majumdar, Sumit ^a   Ford, Brandi M ^a   Dyas, Beverly ^b   Ulrich, Robert G ^b   Sullivan, Vincent J ^a  

^a BD Technologies   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Biotechnology; Chemical stability; Deamidation; Formulation; Protein; Vaccines

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; DEAMINATION; DRUG EFFICACY;

EID: 84872497981     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23422     Document Type: Article

References (29)

1. Baldari CT, Tonello F, Paccani SR, Montecucco C. 2006. Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol 27(9):434-440.
2. Center for Disease Control and Prevention. 2011. Bioterrorism agents/diseases. Atlanta, Georgia: Center for Disease Control and Prevention.
3. Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ. 2011. Anthrax infection. Am J Respir Crit Care Med 184(12):1333-1341.
4. Roos R. 2011. Anthrax countermeasures better than in 2001, but work remains. Center for Infectious Diseases Research and Policy (CIDRP) News. Minneapolis, Minnesota: Center for Infectious Diseases Research and Policy (CIDRP).
5. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Jr.Anderson GW, Gibbs PH, Friedlander AM. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16(11-12):1141-1148.
6. Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, Norris SL, Andrews GP. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24(14):2530-2536.
7. Pitt ML, Little S, Ivins BE, Fellows P, Boles J, Barth J, Hewetson J, Friedlander AM. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87(2):304.
8. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19(32):4768-4773.
9. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A, Velan B. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69(5):2888-2893.
10. Little SF, Leppla SH, Cora E. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56(7):1807-1813.
11. Baillie LW. 2009. Is new always better than old? The development of human vaccines for anthrax. Hum Vaccin 5(12):806-816.
12. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 24(33-34):5950-5959.
13. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL. 2012. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin Vaccin Immunol 19(9):1465-1473.
14. Soliakov A, Kelly IF, Lakey JH, Watkinson A. 2012. Anthrax sub-unit vaccine: The structural consequences of binding rPA83 to Alhydrogel(R). Eur J Pharm Biopharm 80(1):25-32.
15. Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, Bann JG, Middaugh CR. 2012. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. J Pharm Sci 101(11):4118-4128.
16. Ganesan A, Watkinson A, Moore BD. 2012. Biophysical characterisation of thermal-induced precipitates of recombinant anthrax protective antigen: Evidence for kinetically trapped unfolding domains in solid-state. Eur J Pharm Biopharm 82(3):475-484.
17. Powell BS, Enama JT, Ribot WJ, Webster W, Little S, Hoover T, Adamovicz JJ, Andrews GP. 2007. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins 68(2):458-479.
18. Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP, 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG. 2005. Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms. J Infect Dis 191(2):278-288.
19. Xie M, Shahrokh Z, Kadkhodayan M, Henzel WJ, Powell MF, Borchardt RT, Schowen RL. 2003. Asparagine deamidation in recombinant human lymphotoxin: Hindrance by three-dimensional structures. J Pharm Sci 92(4):869-880.
20. Xie M, Schowen RL. 1999. Secondary structure and protein deamidation. J Pharm Sci 88(1):8-13.
21. Wittayanukulluk A, Jiang D, Regnier FE, Hem SL. 2004. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine 22(9-10):1172-1176.
22. Xie M, Aube J, Borchardt RT, Morton M, Topp EM, Vander Velde D, Schowen RL. 2000. Reactivity toward deamidation of asparagine residues in beta-turn structures. J Pept Res 56(3):165-171.
23. Weiss S, Kobiler D, Levy H, Marcus H, Pass A, Rothschild N, Altboum Z. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun 74(1):394-398.
24. Food and Drug Administration, HHS. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 67(105):37988-37998.
25. Singh Y, Klimpel KR, Quinn CP, Chaudhary VK, Leppla SH. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J Biol Chem 266(23):15493-15497.
26. Zomber G, Reuveny S, Garti N, Shafferman A, Elhanany E. 2005. Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J Biol Chem 280(48):39897-39906.
27. Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, Lidgerding BC, Friedlander AM. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt 3):707-715.
28. Sivasubramanian A, Maynard JA, Gray JJ. 2008. Modeling the structure of mAb 14B7 bound to the anthrax protective antigen. Proteins 70(1):218-230.
29. Kelly-Cirino CD, Mantis NJ. 2009. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 77(11):4859-4867.